After stopping a CYP3A4 inducer, since the effects in the inducer decrease, the buprenorphine plasma focus will boost [see CLINICAL PHARMACOLOGY], which could raise or prolong both of those therapeutic effects and adverse reactions and could cause significant respiratory depression.Along with its wanted effects, a medicine could cause some undesira